4th Covalent Drug Discovery and Development Summit Hampton Inn Boston Seaport District, Boston

Covalent drug discovery has entered a defining new phase where scientific validation is no longer the primary barrier; successful clinical translation now takes center stage.

Once limited by concerns around off-target toxicity, covalent approaches are now unlocking undruggable targets and expanding beyond oncology into new therapeutic areas. As next-generation warheads, chemoproteomics, and AI-driven design accelerate innovation, the key challenge is clear: how to translate covalent candidates into safe, effective clinical therapies.

The 4th Covalent Drug Discovery and Development Summit is the only industry forum dedicated to advancing covalent therapeutics end-to-end, from discovery through to IND and early clinical development.

Uniting experts from Bristol Myers Squibb, Novartis, Pfizer, Biogen, Nexo Therapeutics, and Frontier Medicines, this summit goes beyond high-level discussion to deliver data-driven case studies, translational strategies, and real clinical insights.

Join 80+ covalent leaders to:

De-risk your pipeline with early clinical and translational learnings
Overcome selectivity, safety, and PK/PD challenges
Gain candid insights not found in publications
As more covalent drugs enter the clinic, now is the time to turn promise into proof.